<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440801</url>
  </required_header>
  <id_info>
    <org_study_id>CONNECT1</org_study_id>
    <nct_id>NCT03440801</nct_id>
  </id_info>
  <brief_title>A Randomized Comparison of Long-Term Healing Between Biodegradable- Versus Durable-Polymer Everolimus Eluting Stents in STEMI</brief_title>
  <acronym>CONNECT</acronym>
  <official_title>A Randomized COmparison of LoNg-Term Vascular HealiNg bEtween Biodegradable -Polymer (BP) Versus Durable Polymer (DP) Everolimus Eluting Stents in Acute ST-Elevation Myocardial InfarCTion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokorozawa Heart Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tokorozawa Heart Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the acute thrombogenecity and frequency of neoatherosclerotic&#xD;
      lesions and other aspects of long term arterial healing such as the frequency of malapposed&#xD;
      and uncovered stent struts at 3 years among patients treated with either a biodegradable&#xD;
      polymer everolimus-eluting stent (Synergy) or a durable polymer everolimus-eluting stent&#xD;
      (Xience Alpine) for STEMI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DES use has significantly improved clinical outcomes as compared with bare metal stents&#xD;
      (BMS), primarily through a notable reduction in the risk of repeat revascularisation.&#xD;
      However, durable polymer DES have been associated with an increased risk of late and very&#xD;
      late stent thrombosis and the anticipated development of in-stent neoatherosclerosis. In&#xD;
      addition, in-vivo study suggest that different types of polymer among current DES might have&#xD;
      different responses to acute thrombogenecity after stent implantation.&#xD;
&#xD;
      Patients with STEMI are associated with worse long-term clinical outcomes due to&#xD;
      re-infarction and stent thrombosis throughout long-term follow-up. Underlying unstable lesion&#xD;
      which includes ruptured plaque and thin-cap fibroatheroma behind stent strut is a predictor&#xD;
      of neoatherosclerosis formation.&#xD;
&#xD;
      There is no dedicated randomized trial to comparing biodegradable-polymer versus durable&#xD;
      polymer-DES in terms of acute thrombogenecity and long-term healing at 3 years after primary&#xD;
      PCI.&#xD;
&#xD;
      Therefore this study is designed to compare the acute thrombogenecity and frequency of&#xD;
      neoatherosclerotic lesions and other aspects of long term arterial healing at 3 years among&#xD;
      patients treated with either a biodegradable polymer everolimus-eluting stent (Synergy) or a&#xD;
      durable polymer everolimus-eluting stent (Xience Alpine) for STEMI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Anticipated">January 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of neoatheroslcerosis</measure>
    <time_frame>3 years</time_frame>
    <description>Frequency of neoatherosclerosis lesion which is defined as the presence of a fibroatheroma or fibrocalcific plaques or macrophages within the neointima of a stented segment with a longitudinal extension of ≧ 1 mm at three years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Athero-thrombotic material area</measure>
    <time_frame>initial day</time_frame>
    <description>Athero-thrombotic material area (tissue protorusion + isolated intraluminal detect) within the stent strut after primary PCI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Synergy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biodegradable-polymer everolimus-eluting stent Synergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Durable-polymer everolimus-eluting stent Xience</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synergy</intervention_name>
    <description>Biodegradable-polymer everolimus-eluting stent Synergy</description>
    <arm_group_label>Synergy</arm_group_label>
    <arm_group_label>Xience</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience</intervention_name>
    <description>Durable-polymer everolimus-eluting stent Xience</description>
    <arm_group_label>Synergy</arm_group_label>
    <arm_group_label>Xience</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Primary PCI within 24 hours of symptom onset&#xD;
&#xD;
          3. ST-segment elevation of &gt; 1mm in &gt; 2 contiguous leads, or (presumably new) left bundle&#xD;
             branch block, or true posterior MI with ST depression of &gt;1mm in &gt;2 contiguuoius&#xD;
             anterior leads&#xD;
&#xD;
          4. Presence of at least one acute infarct artery target vessel with one or more coronary&#xD;
             artery stenoses in a native coronary artery from 2.25 to 4.5 mm in diameter that can&#xD;
             be covered with one or multiple stents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female ofchildbearing potential (age &lt; 50 years and last menstruation within the last&#xD;
             12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.&#xD;
&#xD;
          2. Known intolerance to aspirin, clopidogrel, prasugrel, ticagrelor, heparin, stainless&#xD;
             steel, cobalt chromium, platinum chromium, everolimus or contrast material&#xD;
&#xD;
          3. Inability to understand and provide informed consent&#xD;
&#xD;
          4. Currently participating in another trial before reaching first endpoint&#xD;
&#xD;
          5. Mechanical complications of acute myocardial infarction&#xD;
&#xD;
          6. Acute myocardial infarction secondary to stent thrombosis or restenosis&#xD;
&#xD;
          7. Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained&#xD;
             throughout the peri-surgical period&#xD;
&#xD;
          8. Noncardiac comorbid conditions are present with life expectancy &lt;3years or that may&#xD;
             result in protocol noncompliance&#xD;
&#xD;
          9. History of bleeding diathesis or known coagulopathy&#xD;
&#xD;
         10. Use of oral anticoagulation&#xD;
&#xD;
         11. Age &gt;90 years&#xD;
&#xD;
         12. LV-function at index procedure &lt;=20%&#xD;
&#xD;
         13. Cancer under active treatment (chemotherapy)&#xD;
&#xD;
         14. Hemodynamic instability following primary PCI&#xD;
&#xD;
         15. Chronic kidey disease (Creatinine - Clearance &lt; 30ml/min)&#xD;
&#xD;
         16. OCT technically not feasible (severe calcification, tortuosity)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Masanori Taniwaki, MD</last_name>
    <phone>+81 429408611</phone>
    <email>grand_wagoneer_797@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorenz Räber, MD, PhD</last_name>
    <phone>+41 316320929</phone>
    <email>lorenz_raeber@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tokorozawa Heart Center</name>
      <address>
        <city>Tokorozawa</city>
        <zip>3591142</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masanori Taniwaki, MD</last_name>
      <phone>+81(0)4-2940-8611</phone>
      <email>grand_wagoneer_797@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokorozawa Heart Center</investigator_affiliation>
    <investigator_full_name>Masanori Taniwaki</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

